Long-term outcomes of transcatheter atrial septal defect closure: a single-center retrospective study
- PMID: 39280031
- PMCID: PMC11392770
- DOI: 10.3389/fcvm.2024.1448967
Long-term outcomes of transcatheter atrial septal defect closure: a single-center retrospective study
Abstract
Background: Transcatheter atrial septal defect (ASD) closure is the primary approach for treating ASD secundum; however, data on long-term outcomes remain limited. This study aimed to elucidate the prevalence of adverse outcomes following transcatheter ASD closure in a diverse population.
Methods: This retrospective cohort study was conducted at the Songklanagarind Hospital and included patients who underwent transcatheter ASD closure between January 2010 and August 2021.
Results: The study included 277 patients who completed follow-up for at least 1 year, with varying ages: <25 years (31%), 25-40 years (19%), 40-60 years (34%), and >60 years (16%). The median follow-up duration was 37 months (interquartile range: 20, 61). The overall mortality rate was 1.8%, and no deaths were attributed to device-related complications. Hospitalization due to heart failure occurred in 0.7% of the cases. Most patients improved or stabilized based on the New York Heart Association functional class. Adverse outcomes included new-onset atrial fibrillation (prevalence: 2.7%) and pulmonary hypertension (prevalence: 0.6%). The resolution of pulmonary hypertension varied among age groups, with 100% resolution in patients <25 years. Multivariate analysis identified male sex, overweight, and history of stroke to be significantly associated with adverse outcomes after transcatheter ASD closure.
Conclusion: Transcatheter ASD closure was safe and effective, with age not being a limiting factor for success. Male sex, being overweight, and a history of stroke were associated with adverse outcomes. These findings contribute to our understanding of the long-term outcomes following ASD closure.
Keywords: atrial fibrillation; atrial septal defect; device closure; patient outcomes; pulmonary hypertension; transcatheter.
© 2024 Honghiranrueng, Roymanee, Wongwaitaweewong, Jarutach and Buntharikpornpun.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Transcatheter closure of secundum atrial septal defect using Cocoon septal occluder: immediate and long-term results.Egypt Heart J. 2022 Aug 13;74(1):59. doi: 10.1186/s43044-022-00298-2. Egypt Heart J. 2022. PMID: 35962873 Free PMC article.
-
Outcome of transcatheter atrial septal defect closure in a nationwide cohort.Ann Med. 2023 Dec;55(1):615-623. doi: 10.1080/07853890.2023.2178669. Ann Med. 2023. PMID: 36786506 Free PMC article.
-
Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices.Cureus. 2023 Jun 8;15(6):e40132. doi: 10.7759/cureus.40132. eCollection 2023 Jun. Cureus. 2023. PMID: 37425612 Free PMC article. Review.
-
[Transcatheter closure of secundum atrial septal defect in children].Zhonghua Er Ke Za Zhi. 2004 Apr;42(4):287-90. Zhonghua Er Ke Za Zhi. 2004. PMID: 15157392 Clinical Trial. Chinese.
-
Secundum atrial septal defects transcatheter closure versus surgery in adulthood: a 2000-2020 systematic review and meta-analysis of intrahospital outcomes.Cardiol Young. 2021 Apr;31(4):541-546. doi: 10.1017/S1047951121001232. Epub 2021 Apr 8. Cardiol Young. 2021. PMID: 33827735
References
-
- Sachdeva R. Atrial septal defects. In: Allen HD, Shaddy RE, Penny DJ, Feltes TF, editors. Moss and Adams’ Heart Disease in Infants, Children, and Adolescents Including the fetus and Young Adult. 9th ed. Philadelphia: Lippincott Williams & Wilkins; (2016). p. 739–56.
LinkOut - more resources
Full Text Sources